Aarti Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on May 06, 2025.
AARTIDRUGS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 18.4 pts more than Nifty Microcap 250 and 19.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Drugs' board approved audited standalone and consolidated financial results for Q4 and FY25 on May 6, 2025. Standalone total income for FY25 rose modestly to about Rs. 2,26,691 lakhs from Rs. 2,17,365 lakhs in FY24, while standalone profit after tax fell to roughly Rs. 11,816 lakhs from Rs. 14,188 lakhs, hurt by exceptional items of about Rs. 1,031 lakhs. Consolidated FY25 PAT declined to around Rs. 12,329 lakhs (from Rs. 17,154 lakhs), though Q4 consolidated PAT grew over 20% year-on-year. Statutory auditors Gokhale & Sathe issued an un-modified (clean) opinion on both standalone and consolidated results. The board also re-appointed M/s GMVP & Associates LLP as Cost Auditor for FY26. The company completed a buyback of 6,65,000 shares at Rs. 900 per share on September 24, 2024.
Mixed signals for shareholders: revenue grew modestly but bottom line contracted on a full-year basis due to exceptional items, while the Q4 consolidated performance showed improvement. The clean audit opinion and routine cost auditor re-appointment are procedural positives, but the full-year PAT decline may weigh on sentiment.